These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 1449519

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Alteration of the inhibitory effect of metyrapone by reduction to metyrapol during the metabolism of methacetin in vivo in mice.
    Maser E, Legrum W.
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Nov; 331(2-3):283-9. PubMed ID: 3937061
    [Abstract] [Full Text] [Related]

  • 23. Subcellular distribution and properties of carbonyl reductase in guinea pig lung.
    Nakayama T, Matsuura K, Nakagawa M, Hara A, Sawada H.
    Arch Biochem Biophys; 1988 Aug 01; 264(2):492-501. PubMed ID: 3041913
    [Abstract] [Full Text] [Related]

  • 24. In vitro characterization of the enzymes involved in the metabolism of 1-furan-2-yl-3-pyridin-2-yl-propenone, an anti-inflammatory propenone compound.
    Lee SK, Kim JH, Seo YM, Kim HC, Kang MJ, Jeong HG, Lee ES, Jeong TC.
    Arch Pharm Res; 2008 Jun 01; 31(6):764-70. PubMed ID: 18563359
    [Abstract] [Full Text] [Related]

  • 25. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases.
    Rosemond MJ, St John-Williams L, Yamaguchi T, Fujishita T, Walsh JS.
    Chem Biol Interact; 2004 Mar 15; 147(2):129-39. PubMed ID: 15013815
    [Abstract] [Full Text] [Related]

  • 26. The enzymology of doxorubicin quinone reduction in tumour tissue.
    Cummings J, Allan L, Willmott N, Riley R, Workman P, Smyth JF.
    Biochem Pharmacol; 1992 Dec 01; 44(11):2175-83. PubMed ID: 1472082
    [Abstract] [Full Text] [Related]

  • 27. Carbonyl reduction of bupropion in human liver.
    Molnari JC, Myers AL.
    Xenobiotica; 2012 Jun 01; 42(6):550-61. PubMed ID: 22339467
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Reduction of the potential anticancer drug oracin in the rat liver in-vitro.
    Szotáková B, Skálová L, Wsól V, Kvasniècková E.
    J Pharm Pharmacol; 2000 May 01; 52(5):495-500. PubMed ID: 10864136
    [Abstract] [Full Text] [Related]

  • 30. Xenobiotic-metabolizing enzyme activity in human non-small-cell derived lung cancer cell lines.
    Falzon M, McMahon JB, Schuller HM.
    Biochem Pharmacol; 1986 Feb 15; 35(4):563-8. PubMed ID: 3004505
    [Abstract] [Full Text] [Related]

  • 31. Reductive metabolism of an alpha,beta-ketoalkyne, 4-phenyl-3-butyn-2-one, by rat liver preparations.
    Kitamura S, Kohno Y, Okamoto Y, Takeshita M, Ohta S.
    Drug Metab Dispos; 2002 Apr 15; 30(4):414-20. PubMed ID: 11901095
    [Abstract] [Full Text] [Related]

  • 32. Synthesis of N-oxide derivatives of metyrapone and their detection as in vitro metabolites.
    Crooks PA, Damani LA, Cowan DA.
    J Pharm Pharmacol; 1981 May 15; 33(5):309-12. PubMed ID: 6116779
    [Abstract] [Full Text] [Related]

  • 33. Characterization of microsomal and cytoplasmic metyrapone reducing enzymes from mouse liver.
    Maser E.
    Arch Toxicol Suppl; 1989 May 15; 13():271-4. PubMed ID: 2476105
    [No Abstract] [Full Text] [Related]

  • 34. Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides.
    Smith TJ, Stoner GD, Yang CS.
    Cancer Res; 1995 Dec 01; 55(23):5566-73. PubMed ID: 7585636
    [Abstract] [Full Text] [Related]

  • 35. Metabolism of metyrapone. III. Formation of an alpha-pyridone metabolite by rat hepatic soluble enzymes.
    Damani LA, Crooks PA, Cowan DA.
    Drug Metab Dispos; 1981 Dec 01; 9(3):270-3. PubMed ID: 6113939
    [Abstract] [Full Text] [Related]

  • 36. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
    Skarydová L, Skarka A, Novotná R, Zivná L, Martin HJ, Wsól V, Maser E.
    Toxicology; 2009 Oct 01; 264(1-2):52-60. PubMed ID: 19635524
    [Abstract] [Full Text] [Related]

  • 37. Carbonyl reduction of the potential cytostatic drugs benfluron and 3,9-dimethoxybenfluron in human in vitro.
    Skálová L, Nobilis M, Szotáková B, Kondrová E, Savlík M, Wsól V, Pichard-Garcia L, Maser E.
    Biochem Pharmacol; 2002 Jul 15; 64(2):297-305. PubMed ID: 12123751
    [Abstract] [Full Text] [Related]

  • 38. In vitro metabolism of fenofibric acid by carbonyl reducing enzymes.
    Malátková P, Kanavi M, Nobilis M, Wsól V.
    Chem Biol Interact; 2016 Oct 25; 258():153-8. PubMed ID: 27599626
    [Abstract] [Full Text] [Related]

  • 39. Evidence of metyrapone reduction by two Mycobacterium strains shown by 1H NMR.
    Combourieu B, Besse P, Sancelme M, Maser E, Delort AM.
    Biodegradation; 2004 Apr 25; 15(2):125-32. PubMed ID: 15068373
    [Abstract] [Full Text] [Related]

  • 40. p-nitrosophenol reduction by liver cytosol from ADH-positive and -negative deermice (Peromyscus maniculatus).
    Dudley BF, Winston GW.
    Arch Biochem Biophys; 1995 Feb 01; 316(2):879-85. PubMed ID: 7532387
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.